中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites

DOI: 10.3969/j.issn.1001-5256.2020.07.015
Research funding:

 

  • Published Date: 2020-07-20
  • Objective To investigate the difference in intestinal flora between hepatitis B liver cirrhosis( HBLC) patients with or without ascites. Methods A total of 57 patients with HBLC who visited Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from October to December 2016 were enrolled,among whom 30 had no ascites( HBLC-WOA group) and 27 had ascites without spontaneous peritonitis( SBP)( HBLC-WA group),and 28 healthy volunteers were enrolled as healthy controls( HC group). Intestinal flora was compared between the two groups of HBLC patients using 16 S rRNA sequencing. The Wilcoxon rank sum test was used for comparison of categorical data between two groups,and the Mann-Whitney U test was used for comparison of continuous data between two groups;the Kruskal-Wallis H test was used for comparison of continuous variables between more than two groups. Multiple hypothesis tests were used for comparison of relative abundance between species and was adjusted by Benjamini and Hochberg false discovery rate( fdr),and Pfdr< 0. 05 was considered statistically significant. The Spearman rank correlation test was used for correlation analysis. An analysis of similarity( ANOSIM) and a non-parametric multivariate analysis of variance( Adonis) were used for comparison between groups under different conditions. Results The abundance of fecal microbiota gradually decreased with the appearance of ascites in HBLC patients( P = 0. 042).There were significant differences between the HBLC-WOA group and the HC group( ANOSIM: R = 0. 159,P = 0. 001; Adonis: R2=0. 067,P = 0. 001) and between the HBLC-WA group and the HC group( ANOSIM: R = 0. 323,P = 0. 001; Adonis: R2= 0. 107,P =0. 001). At the genus level,compared with the HC group,the HBLC-WA group had significant reductions in the abundance of Subdoligranulum and Pseudobutyrivibrio( P < 0. 01 and P < 0. 001) and significant increases in the abundance of Enterobacter,Escherichia,and Veillonella( P < 0. 05,P < 0. 001,and P < 0. 01). Escherichia and Veillonella were positively correlated with Child-Turcotte-Pugh( CTP) score,prothrombin time,and international normalized ratio and were negatively correlated with serum albumin( Alb) level( all P <0. 05). Pseudobutyrivibrio,norank _f _ Lachnospiraceae,unclassified _ f _ Lachnospiraceae,and Blautia were positively correlated with Alb level and were negatively correlated with CTP score and C-reactive protein level( all P < 0. 05). The KEGG pathway analysis showed that with the appearance of ascites,there were gradual increases in the abundance of the pathways associated with transcription-related proteins,alpha-linolenic acid metabolism,Staphylococcus aureus infection,bacterial invasion of epithelial cells,and bile secretion( all Pfdr< 0. 05),as well as a gradual reduction in the abundance of the pathway associated with the biosynthesis of flavonoids( Pfdr< 0. 05). The pathway associated with bacterial invasion of epithelial cells was positively correlated with the abundance of Escherichia( P < 0. 001),and the abundance of Enterobacter was positively correlated with the pathway of bile secretion( P < 0. 001). Conclusion Intestinal flora disturbance is observed in HBLC-WA patients,featuring the reductions in the abundance of Subdoligranulum and Pseudobutyrivibrio belonging to Firmicutes and the increases in the abundance of Enterobacter and Escherichia belonging to Proteobacteria. Enterobacter may be involved in the pathway of bile secretion,and Escherichia may be involved in the pathway associated with bacterial invasion of epithelial cells. It is suggested that regulation of intestinal flora,as well as the prophylactic treatment of SBP,should be considered for HBLC-WA patients without SBP.

     

  • [1]LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.
    [2]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:The major impact of China[J].Hepatology,2014,60(6):2099-2108.
    [3]HENDRIKX T,SCHNABL B.Antimicrobial proteins:Intestinal guards to protect against liver disease[J].J Gastroenterol,2019,54(3):209-217.
    [4]SENDER R,FUCHS S,MILO R.Revised estimates for the number of human and bacteria cells in the body[J].PLo S Biol,2016,14(8):e1002533.
    [5]HARTMANN P,CHEN WC,SCHNABL B.The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease[J].Front Physiol,2012,3:402.
    [6]LIN R,ZHOU L,ZHANG J,et al.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.
    [7]BHAT M,ARENDT BM,BHAT V,et al.Implication of the intestinal microbiome in complications of cirrhosis[J].World J Hepatol,2016,8(27):1128-1136.
    [8]GINS P,QUINTERO E,ARROYO V,et al.Compensated cirrhosis:Natural history and prognostic factors[J].Hepatology,1987,7(1):122-128.
    [9]D'AMICO G,GARCIA-TSAO G,PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:A systematic review of 118studies[J].J Hepatol,2006,44(1):217-231.
    [10]van ERPECUM KJ.Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis[J].Scand J Gastroenterol Suppl,2006,243:79-84.
    [11]GINS P,CRDENAS A,ARROYO V,et al.Management of cirrhosis and ascites[J].N Engl J Med,2004,350(16):1646-1654.
    [12]BENTEN D,WIEST R.Gut microbiome and intestinal barrier failure-the“Achilles heel”in hepatology?[J].J Hepatol,2012,56(6):1221-1223.
    [13]WIEST R,KRAG A,GERBES A.Spontaneous bacterial peritonitis:Recent guidelines and beyond[J].Gut,2012,61(2):297-310.
    [14]WIEST R,GARCIA-TSAO G.Bacterial translocation(BT)in cirrhosis[J].Hepatology,2005,41(3):422-433.
    [15]NOLAN JP.The role of intestinal endotoxin in liver injury:A long and evolving history[J].Hepatology,2010,52(5):1829-1835.
    [16]GILL SR,POP M,DEBOY RT,et al.Metagenomic analysis of the human distal gut microbiome[J].Science,2006,312(5778):1355-1359.
    [17]CHEN Y,YANG F,LU H,et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology,2011,54(2):562-572.
    [18]SANTIAGO A,POZUELO M,POCA M,et al.Alteration of the serum microbiome composition in cirrhotic patients with ascites[J].Sci Rep,2016,6:25001.
    [19]KANG Y,CAI Y.Gut microbiota and hepatitis-B-virus-induced chronic liver disease:Implications for faecal microbiota transplantation therapy[J].J Hosp Infect,2017,96(4):342-348.
    [20] QIN J,LI R,RAES J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464(7285):59-65.
    [21]LU H,WU Z,XU W,et al.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection.Intestinal microbiota of HBV cirrhotic patients[J].Microb Ecol,2011,61(3):693-703.
    [22]TUOMISTO S,PESSI T,COLLIN P,et al.Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics[J].BMC Gastroenterol,2014,14:40.
    [23]BAJAJ JS,BETRAPALLY NS,HYLEMON PB,et al.Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J].Hepatology,2015,62(4):1260-1271.
    [24]QIN N,YANG F,LI A,et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature,2014,513(7516):59-64.
    [25]WEI X,YAN X,ZOU D,et al.Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J].BMC Gastroenterol,2013,13:175.
    [26]FAITH JJ,GURUGE JL,CHARBONNEAU M,et al.The longterm stability of the human gut microbiota[J].Science,2013,341(6141):1237439.
    [27]BAJAJ JS,HEUMAN DM,HYLEMON PB,et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol,2014,60(5):940-947.
    [28]BALMER ML,SLACK E,de GOTTARDI A,et al.The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota[J].Sci Transl Med,2014,6(237):237ra66.
    [29]PONZIANI FR,ZOCCO MA,CERRITO L,et al.Bacterial translocation in patients with liver cirrhosis:Physiology,clinical consequences,and practical implications[J].Expert Rev Gastroenterol Hepatol,2018,12(7):641-656.
    [30]TANG R,WEI Y,LI Y,et al.Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J].Gut,2018,67(3):534-541.
    [31]YANG R,XU Y,DAI Z,et al.The immunologic role of gut microbiota in patients with chronic HBV infection[J].J Immunol Res,2018,2018:2361963.
    [32]TILG H,CANI PD,MAYER EA.Gut microbiome and liver diseases[J].Gut,2016,65(12):2035-2044.
  • Relative Articles

    [1]Ying TU, Xue LI, Meijuan CHEN, Huaqian XU, Shanhong TANG. Value of platelet count and related scoring models in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2023.06.009
    [2]Lu WANG, Wenxiong XU, Shu ZHU, Xuejun LI, Yuanli CHEN, Chan XIE, Liang PENG. Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(5): 1053-1058. doi: 10.3969/j.issn.1001-5256.2022.05.015
    [3]Xiao YU, Guobing WU, Aibin ZHANG, Xiaolong CHENG, Min LIU, Zenan HU, Ya ZHENG, Yuping WANG, Zhaofeng CHEN. Role of platelets in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1426-1430. doi: 10.3969/j.issn.1001-5256.2022.06.043
    [4]Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
    [5]Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of FibroScan combined with gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis in patients with chronic hepatitis B:A preliminary study[J]. Journal of Clinical Hepatology, 2019, 35(2): 334-337. doi: 10.3969/j.issn.1001-5256.2019.02.018
    [6]Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis stage in chronic hepatitis B patients in Guangdong, China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1204-1208. doi: 10.3969/j.issn.1001-5256.2018.06.015
    [7]Li PingYing, Yang YongGeng, Lu LunGen, Zhu ZhiYong, Wang YaPing, Ma YingCai. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2412-2415. doi: 10.3969/j.issn.1001-5256.2017.12.036
    [8]Lin Yan, Li Xun. Research advances in the role of platelets in liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(11): 2243-2246. doi: 10.3969/j.issn.1001-5256.2017.11.043
    [9]Chen Nian, Huang WeiE, Su MingHua, Jiang JianNing. Correlation between platelet indices and liver pathological staging: an analysis of 167 patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(1): 106-109. doi: 10.3969/j.issn.1001-5256.2016.01.019
    [10]Li Qiang, Huang YuXian, Chen Liang. Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J]. Journal of Clinical Hepatology, 2016, 32(6): 1125-1129. doi: 10.3969/j.issn.1001-5256.2016.06.021
    [11]Zheng JunFu, Cai ZhaoHua, Zhang Xin, Lou JinLi, Zhao WenMin, Li Peng, Li Bing, Li Lei, Dong PeiLing, Ding HuiGuo. Value of single or combined measurement of serum PCT,peripheral WBC,and WBC/PCT for early diagnosis of bacterial infection in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 209-213. doi: 10.3969/j.issn.1001-5256.2015.02.016
    [12]Gao Chun, Fang Long, Yao ShuKun. Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 921-925. doi: 10.3969/j.issn.1001-5256.2014.09.021
    [13]Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022
    [14]Ding ShengNan, Yang WeiMin, Niu JunQi. Changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(6): 556-559. doi: 10.3969/j.issn.1001-5256.2014.06.020
    [15]Jin GuoHua, Po YunFeng, Chen ZhaoJie. Comparison on hematoblastic relevant parameter from patients with liver cirrhosis after heptitis B and patients with alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(2): 102-104.
  • Cited by

    Periodical cited type(12)

    1. 张玉婷,施欢,李虤,沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
    2. 杜乔慧,吴克俭,王争争. GP73、GPR对慢性乙型肝炎患者肝硬化的诊断价值. 胃肠病学和肝病学杂志. 2022(07): 758-763 .
    3. 鲁荣华. 血清IL-2和IL-10对重度慢性乙型肝炎患者糖皮质激素治疗预后的评估价值. 中国卫生工程学. 2020(01): 83-85 .
    4. 毛桂芸,张永飞,郭延生,陶金忠. 山楂对围产期奶牛肝功能和血脂的影响. 中国奶牛. 2020(08): 36-39 .
    5. 陈晓玲,宋倩. 剪切波弹性成像和γ-谷氨酰转肽酶/血小板比用于诊断慢性乙型肝炎患者肝纤维化. 中国医学影像技术. 2020(10): 1499-1503 .
    6. 黄春明,杨湛,聂玉强,胡中伟,周永健,詹远京,郭家伟,余卫华. FibroScan联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化的初步探讨. 临床肝胆病杂志. 2019(02): 334-337 . 本站查看
    7. 张小磊. 血清ALT、AST、GGT、HBV-DNA联合检测在慢性乙型肝炎病情评估中的应用. 内蒙古医学杂志. 2019(02): 211-212 .
    8. 尹国云. 瞬时弹性超声检测对蒙古族地区慢性乙型病毒性肝炎患者抗病毒治疗临床指导意义的研究. 世界复合医学. 2019(06): 90-92+114 .
    9. 黄春明,胡中伟,聂玉强,周永健,詹远京,郭家伟,余卫华. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值. 胃肠病学和肝病学杂志. 2019(08): 915-918 .
    10. 黄春明,杨湛,聂玉强,胡中伟,周永健,詹远京,郭家伟,余卫华. GGT/PLT比值对广东地区慢性乙型肝炎患者肝纤维化分期的预测价值. 临床肝胆病杂志. 2018(06): 1204-1208 . 本站查看
    11. 李曼,李涛,刘振杰,曹永坚,钟伟国,余婷玉,何敏,徐宁. 以血清学指标比值为变量的肝纤维化诊断模型构建与评价. 山东医药. 2018(18): 17-20 .
    12. 李曼,张军,李涛,罗强,钟伟国,李嘉胜,徐宁. ADA/PLT、ALP/PLT比值对肝纤维化的诊断价值. 中国实验诊断学. 2017(11): 1923-1926 .

    Other cited types(3)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1350) PDF downloads(160) Cited by(15)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return